FAQ: NeuroOne's Record Revenue Growth and Investor Webinar
Summary
NeuroOne Medical Technologies announced preliminary unaudited product revenue growth of 163% to a record $9.1 million for fiscal year 2025, driven by expanded customer interest in their OneRF® Ablation system for epilepsy treatment.
What is the main announcement from NeuroOne?
NeuroOne announced preliminary unaudited product revenue growth of 163% to a record $9.1 million for fiscal year 2025, compared to $3.5 million in fiscal 2024.
Why is this revenue growth significant?
This represents a 163% year-over-year increase and sets a new revenue record for the company, indicating strong market adoption of their medical technologies.
What drove NeuroOne’s revenue growth in 2025?
The growth was driven by expanded customer interest and positive outcomes with the OneRF® Ablation system for patients suffering with seizures associated with epilepsy.
When will complete financial results be available?
Complete financial results for the quarter are expected to be announced in December 2025.
What is the OneRF technology platform?
The OneRF technology platform includes minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation for patients suffering from neurological disorders like epilepsy.
When is the virtual investor webinar and how can I join?
The webinar is on Tuesday, October 7, 2025 at 8:30 a.m. Eastern Standard Time. Participants can join via webcast link or dial-in numbers: U.S. Toll Free 888-506-0062 or International 973-528-0011 with access code 619723.
Who will be presenting at the investor webinar?
Dave Rosa, Chief Executive Officer, will provide a business overview and discuss recent milestones, while Ron McClurg, Chief Financial Officer, will provide a financial overview.
What was NeuroOne’s cash position as of September 30, 2025?
As of September 30, 2025, the Company had preliminary cash and cash equivalents of $6.6 million.
How long will the webinar recording be available?
A playback of the call will be available through October 21, 2025. To listen, call 877-481-4010 (U.S.) or 919-882-2331 (international) using replay passcode 53045.
What neurological conditions does NeuroOne’s technology address?
NeuroOne’s technology addresses epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 244199